Canaccord Genuity Reiterates a 'Buy' on Momenta Pharmaceuticals (MNTA); Copaxone Inequitable Conduct Trial Day 3 Update
Tweet
Share
E-mailGet Alerts MNTA Hot Sheet
Price: $52.48 --0%
Rating Summary:
8 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Rating Summary:
8 Buy, 11 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Momenta Pharmaceuticals (NASDAQ: MNTA), PT $27.
Canaccord analyst, Ritu Baral, said, "We think sales of m-platform enoxaparin (Momenta/Sandoz’ generic Lovenox) are strong but Teva’s generic enox may be out in Q4/11. We think M356, Momenta/Sandoz’ generic Copaxone, is approvable without large clinical trials and Momenta will progress its patent suit in Sept.’11.Our $27 target is based on a sum-of-the-parts analysis."
For more ratings news on Momenta Pharmaceuticals click here and for the rating history of Momenta Pharmaceuticals click here.
Shares of Momenta Pharmaceuticals closed at $19.54 yesterday.
Canaccord analyst, Ritu Baral, said, "We think sales of m-platform enoxaparin (Momenta/Sandoz’ generic Lovenox) are strong but Teva’s generic enox may be out in Q4/11. We think M356, Momenta/Sandoz’ generic Copaxone, is approvable without large clinical trials and Momenta will progress its patent suit in Sept.’11.Our $27 target is based on a sum-of-the-parts analysis."
For more ratings news on Momenta Pharmaceuticals click here and for the rating history of Momenta Pharmaceuticals click here.
Shares of Momenta Pharmaceuticals closed at $19.54 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Viking Holdings (VIK) PT Raised to $82 at Mizuho
- Bernstein SocGen on Meta Platforms Inc. (META): 'Risk-reward remains attractive'
- DA Davidson Starts Everus (ECG) at Buy
Create E-mail Alert Related Categories
Analyst CommentsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
